期刊文献+

AIB1在乳腺良、恶性病变组织中的表达及临床意义 被引量:1

Expression of nuclear receptor coactivator AIB1 in breast cancer and its clinical significance
下载PDF
导出
摘要 目的探讨乳腺良、恶性组织中乳腺癌扩增性抗原1(amplified in breast cancer 1,AIB1)蛋白的表达与临床意义。方法采用免疫组织化学方法检测120例乳腺癌组织、40例良性乳腺病变、20例癌旁正常乳腺组织中AIB1的表达,并探讨该蛋白与乳腺癌患者的肿瘤大小、组织学分级、淋巴结有无转移及基因分型等的关系。结果乳腺癌组织中AIB1过表达(40.0%)显著高于正常乳腺组织(10.0%)和乳腺良性病变组织(15.0%)(P<0.05)。在乳腺癌组织中,组织分级Ⅲ级组的过表达率(62.0%)显著高于Ⅰ级组(10.5%)和Ⅱ级组(29.4%)(P<0.05))。腋淋巴结转移组中的过表达率(53.8%)显著高于淋巴结无转移组(14.3%)(P<0.05)。乳腺癌组织中,AIB1蛋白表达率在ER阳性组(45.2%)、阴性组(27.8%)间的差异无统计学意义(P=0.0741),PR阳性组(42.9%)、阴性组(34.9%)间的差异无统计学意义(P=0.393),而HER2阳性组的AIB1过表达率(51.5%)显著高于阴性组(25.0%)(P<0.05)。乳腺癌组AIB1蛋白的阳性表达率与乳腺癌不同基因分型亚型明显相关(P<0.05)。结论乳腺癌中AIB1过表达与乳腺癌的发生、发展及肿瘤的恶性程度密切相关,AIB1蛋白高表达可能提示临床预后不良。 Objective To investigate the expression of amplified in breast cancer 1(AIB1) protein in breast cancer and its clinical significance.Methods The expressions of AIB1 protein in 120 tissue specimens of breast cancer,20 specimens of normal breast tissue and 40 benign breast lesions were examined by immunohistochemistry.The associations of AIB1 expression with tumor size,histological grades,lymph nodes metastasis and genotype were analyzed.Results The expression rate of AIB1 protein in breast cancer(40.0%) was significantly higher than those in benign lesions(15.0%) and normal breast tissues(10.0%)(P 0.05).The expression of AIB1 in grade Ⅲ cancer(62.0%) was higher than those in gradeⅠ(10.5%) and gradeⅡ(29.4%) cancer(P 0.05).The expression rate of AIB1 protein in cases with metastatic lymph nodes(53.8%) was higher than that in those with no metastatic lymph nodes(14.3%)(P 0.05).The expression rate was higher in patients with HER2(+)(51.5%) than that in those with HER2(-)(25.0%)(P 0.05);however,AIB1 expression was not correlated with ER or ER/PR status(both P 0.05) in breast cancer tissue.The over expression rate of AIB1 had correlation with sub-genotype(P 0.05) of breast cancer.Conclusions Upregulation of AIB1 expression is involved in the carcinogenesis and development of breast cancer;it may be used as an indicator for malignant biological behavior and poor prognosis.
出处 《实用肿瘤杂志》 CAS 2012年第6期593-599,共7页 Journal of Practical Oncology
基金 河北省科学技术厅基金(11276103D-70)
关键词 乳腺肿瘤 病理学 基因扩增 免疫组织化学 预后 基因表达 抗药性 肿瘤 雌激素拮抗剂 治疗应用 breast neoplasms/pathology gene amplification immunohistochemistry prognosis gene expression drug resistance neoplasm estrogen antagonists/therapeutic use
  • 相关文献

参考文献23

  • 1Saegusa M, Okayasu I. Changes in expression of estrogenreceptors a and (? in relation to progesterone receptor andpS2 status in normal and malignant endometrium [ J]. JpnJ Cancer Res,2000,91 (5) :510-518.
  • 2Nielsen TO, Hsu FD, Jensen K, et al.Immunohistochemical and clinical characterization of thebasal-like subtype of invasive breast carcinoma [ J ] . ClinCancer Res,2004,10( 16) :5367 -5374.
  • 3Richardson AL, Wang ZC, de Nicolo A, et al. Xchromosomal abnormalities in basallike human breastcancer [ J]. Cancer Cell,2006,9(2) :12l - 132.
  • 4Harigopal M,Heymann J,Ghosh S,et al. Estrogenreceptor co-activator ( AIB1 ) protein expression byautomated quantitative analysis ( AQUA) in a breastcancer tissue microarray and association wit patientoutcome [ J]. Breast Cancer Res Treat,2009,115 (1 ) :77-85.
  • 5Zhao C,Yasui K,Lee CJ,et al. Elevated expression levelsof NCOA3, TOPI,and TFAP2C in breast tumors aspredietors of poor prognosis [ J]. Cancer,2003 ,98( 1) :18-23.
  • 6Hudelist G, Czerwenka K, Kubista E, et al. Expression ofsex steroid receptors and their co-factors in normal andmalignant breast tissue: AIB1 is a carcinoma-specificcoactivator [ J]. Breast Cancer Res Treat,2003 ,78 (2):193 -204.
  • 7Henke RT, Eun Kim S, Maitra A,et al. Expressionanalysis of mRNA in formalin-fixed, paraffin-embeddedarchival tissues by mRNA in situ hybridization [ J ].Methods,2006,38(4) :253 -262.
  • 8韩肖燕,张雪梅,陈悦,杨开选,郄明蓉.AIB1蛋白在妇科肿瘤中的表达[J].四川大学学报(医学版),2007,38(2):246-249. 被引量:5
  • 9韩肖燕,陈悦,侯敏敏,杨开选,陈莹莹,郄明蓉.上皮性卵巢癌AIB1蛋白表达水平及与雌、孕激素受体表达的相关性研究[J].实用肿瘤杂志,2009,24(4):341-344. 被引量:7
  • 10Ivshina AV, George J, Senko 0, et al. Genetic reclassi-fication of histologic grade delineates new clinical sub-types of breast cancer [ J]. Cancer Res,2006,66(21):10292-10301.

二级参考文献78

  • 1韩肖燕,张雪梅,陈悦,杨开选,郄明蓉.AIB1蛋白在妇科肿瘤中的表达[J].四川大学学报(医学版),2007,38(2):246-249. 被引量:5
  • 2Kuang SQ,Liao L,Wang S,et al.Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis[J].Cancer Res,2005,65(17):7993-8002.
  • 3Liao L,Kuang SQ,Yuan Y,et al.Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1[J].J Steroid Biochem Mol Biol,2002,83(1-5):3-14.
  • 4Henke RT,Haddad BR,Kim SE,et al.Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma[J].Clin Cancer Res,2004,10(18):6134-6142.
  • 5Tanner MM,Grenman S,Koul A,et al.Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer[J].Clin Cancer Res,2000,6(5):1833-1839.
  • 6Anzick SL,Kononen J,Walker RL,et al.AIB1,a steroid receptor coactivator amplified in breast and ovarian cancer[J].Science (Wash.DC),1997,277(5328):965-968.
  • 7Bouras T,Southey MC,Venter DJ.Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu[J].Cancer Res,2001,61(3):903-907.
  • 8Glaeser M,Floetotto T,Hanstein B,et al.Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas[J].Horm Metab Res,2001,33(3):121-126.
  • 9Sakakura C,Hagiwara A,Yasuoka R,et al.Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers[J].Int J Cancer,2000,89(3):217-223.
  • 10Xie D,Sham JS,Zeng WF,et al.Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma[J].Hum Pathol,2005,36(7):777-783.

共引文献17

同被引文献7

  • 1SEIFERT H, GEORGIOU A, ALEXANDER H,et al. Poor perfor-mance status (IXS) is an indication for an aggressive approach to necadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC) [J]. Gynecd Onco/,2015,139(2) :216 -220.
  • 2KIM K H, JELOVAC D, ARMSTRONG D K,et al. Phase lb safety study of farletuzumab, carboplatin and pegylated Lipnsomal doxorubi- tin in patients with platinum - sensitive epithelial ovarian cancer[ J l- Gynecol Onco1,2015,28 ( 15 ) :302 - 331.
  • 3SOLi~TORMOS G, DUFFY M J, OTHMAN ABU HASSAN S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: upda- ted guidelines from the european group on tumor markers [ J ]. lnt J Gynecol Cancer,2016,26 ( 1 ) :43 - 51.
  • 4KARIMI- ZARCHI M, MORTAZAVIZADEH S M, BASHARDUST N, et al. The clinicopathologic characteristics and 5 - year survival rate of epithelial ovarian cancer in Yazd, h'an [ J ]. Electron Physician,2015,7 (6) :1399 - 1406.
  • 5WARGON V, RIGGIO M, GIULIANELLI S,et al. Progestin and an- tiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SKIRT recruitment to the CCND1 and MYC promo- ters[ J]. Iat J Cancer,2015,136( I 1 ) :2680 - 2692.
  • 6韩肖燕,陈悦,侯敏敏,杨开选,陈莹莹,郄明蓉.上皮性卵巢癌AIB1蛋白表达水平及与雌、孕激素受体表达的相关性研究[J].实用肿瘤杂志,2009,24(4):341-344. 被引量:7
  • 7朱益平,刘银华,盛莉莉,吉兆宁.AIB1蛋白在卵巢肿瘤中的表达及意义[J].皖南医学院学报,2012,31(6):435-437. 被引量:2

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部